121 related articles for article (PubMed ID: 23743310)
21. Programmatic impact of using QuantiFERON®-TB Gold in routine contact investigation activities.
Grinsdale JA; Ho CS; Banouvong H; Kawamura LM
Int J Tuberc Lung Dis; 2011 Dec; 15(12):1614-20. PubMed ID: 22118167
[TBL] [Abstract][Full Text] [Related]
22. Comparison of QuantiFERON-TB Gold test and tuberculin skin test for the identification of latent Mycobacterium tuberculosis infection in lupus patients.
Yilmaz N; Zehra Aydin S; Inanc N; Karakurt S; Direskeneli H; Yavuz S
Lupus; 2012 Apr; 21(5):491-5. PubMed ID: 22140142
[TBL] [Abstract][Full Text] [Related]
23. Demographics and prevalence of positive QuantiFERON-TB Gold In-Tube test in renal transplant candidates.
Simkins J; Kraus K; Morris MI
Transpl Infect Dis; 2016 Feb; 18(1):5-13. PubMed ID: 26534762
[TBL] [Abstract][Full Text] [Related]
24. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
Sato S; Nagai H
Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
[TBL] [Abstract][Full Text] [Related]
25. Dynamic changes in positive interferon-gamma release assay in a dialysis population: An observational cohort study.
Shu CC; Wu VC; Yang FJ; Hsu CL; Pan SC; Wang JY; Wang JT; Yu CJ; Lee LN
J Infect; 2013 Dec; 67(6):529-35. PubMed ID: 23933475
[TBL] [Abstract][Full Text] [Related]
26. [Prevalence of latent infection with Mycobacterium tuberculosis in Mazovia Region using interferon gamma release assay after stimulation with specific antigens ESAT-6 and CFP-10].
Kuś J; Demkow U; Lewandowska K; Korzeniewska-Koseła M; Rabczenko D; Siemion-Szcześniak I; Białas-Chromiec B; Bychawska M; Sapigórski P; Maciejewski J
Pneumonol Alergol Pol; 2011; 79(6):407-18. PubMed ID: 22028119
[TBL] [Abstract][Full Text] [Related]
27. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.
Esfahani K; Aspler A; Menzies D; Schwartzman K
Int J Tuberc Lung Dis; 2011 Oct; 15(10):1340-6. PubMed ID: 22283892
[TBL] [Abstract][Full Text] [Related]
28. Impact of Baseline Tuberculin Skin Test and Isoniazid Chemoprophylaxis on Subsequent Quantiferon-TB Gold In-Tube Performance in Young Children Assessed After Tuberculosis Contact in Catalonia.
Velasco-Arnaiz E; Soriano-Arandes A; Espiau M; Altet N; Fortuny C; Monsonís M; Tebruegge M; Noguera-Julian A
Pediatr Infect Dis J; 2020 Feb; 39(2):e22-e25. PubMed ID: 31738322
[TBL] [Abstract][Full Text] [Related]
29. Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort.
Lee SW; Lee SH; Yim JJ
Infection; 2012 Aug; 40(4):431-5. PubMed ID: 22585454
[TBL] [Abstract][Full Text] [Related]
30. The impact of anti-tuberculous antibiotics and corticosteroids on cytokine production in QuantiFERON-TB Gold In Tube assays.
Clifford V; Zufferey C; Germano S; Ryan N; Leslie D; Street A; Denholm J; Tebruegge M; Curtis N
Tuberculosis (Edinb); 2015 May; 95(3):343-9. PubMed ID: 25837441
[TBL] [Abstract][Full Text] [Related]
31. Advances in diagnosis and treatment of latent tuberculosis infection.
Chapman HJ; Lauzardo M
J Am Board Fam Med; 2014; 27(5):704-12. PubMed ID: 25201941
[TBL] [Abstract][Full Text] [Related]
32. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.
Jiménez-Fuentes MA; de Souza-Galvao ML; Mila Augé C; Solsona Peiró J; Altet-Gómez MN
Int J Tuberc Lung Dis; 2013 Mar; 17(3):326-32. PubMed ID: 23407221
[TBL] [Abstract][Full Text] [Related]
33. Screening for Mycobacterium tuberculosis infection among healthcare workers in New Zealand: prospective comparison between the tuberculin skin test and the QuantiFERON-TB Gold In-Tube assay.
Freeman JT; Marshall RJ; Newton S; Austin P; Taylor S; Chew TC; Gavaghan S; Roberts SA
N Z Med J; 2012 Feb; 125(1349):21-9. PubMed ID: 22327155
[TBL] [Abstract][Full Text] [Related]
34. [Interpreting "equivocal" results obtained from the QuantiFERON-TB Gold In-Tube test in contact investigations].
Komukai J; Matsumoto K; Hirota S; Yoshida H; Koda S; Terakawa K; Shimouchi A
Kekkaku; 2013 Mar; 88(3):301-4. PubMed ID: 23672171
[TBL] [Abstract][Full Text] [Related]
35. Influence of previous tuberculin skin test on serial IFN-γ release assays.
Sauzullo I; Massetti AP; Mengoni F; Rossi R; Lichtner M; Ajassa C; Vullo V; Mastroianni CM
Tuberculosis (Edinb); 2011 Jul; 91(4):322-6. PubMed ID: 21664872
[TBL] [Abstract][Full Text] [Related]
36. QuantiFERON-TB Gold In-Tube test for diagnosis of latent tuberculosis (TB) infection in solid organ transplant candidates: a single-center study in an area endemic for TB.
Ahmadinejad Z; Azmoudeh Ardalan F; Razzaqi M; Davoudi S; Jafarian A
Transpl Infect Dis; 2013 Feb; 15(1):90-5. PubMed ID: 23173720
[TBL] [Abstract][Full Text] [Related]
37. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
Fluegge KR
J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
[TBL] [Abstract][Full Text] [Related]
38. Treatment of latent tuberculosis infection.
Parekh MJ; Schluger NW
Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
[TBL] [Abstract][Full Text] [Related]
39. Serial testing of refugees for latent tuberculosis using the QuantiFERON-gold in-tube: effects of an antecedent tuberculin skin test.
Baker CA; Thomas W; Stauffer WM; Peterson PK; Tsukayama DT
Am J Trop Med Hyg; 2009 Apr; 80(4):628-33. PubMed ID: 19346390
[TBL] [Abstract][Full Text] [Related]
40. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis.
Higuchi K; Harada N; Mori T
Respirology; 2008 May; 13(3):468-72. PubMed ID: 18399875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
